Hospital-Treated Gram-Negative Infections – Current Treatment – Detailed, Expanded Analysis (US)
Generic antibiotics continue to dominate the hospital-treated gram-negative infection (GNI) therapy market. Most inpatients are successfully treated empirically with such agents, and thus branded products like Allergan / AbbVie’s Avycaz, Shionogi’s Fetroja, Paratek Pharmaceuticals’ Nuzyra, Merck & Co.’s Recarbrio, Innoviva / Entasis’s Xacduro, Tetraphase Pharmaceuticals’ Xerava, Cipla Therapeutics’ Zemdri, and Merck & Co.’s Zerbaxa are typically restricted to later lines of therapy. Yet, increasing rates of antimicrobial resistance have created the need for safer products to effectively treat drug-resistant GNIs. In this analysis, we explore brand use in this market based on factors such as activity against key drug-resistant pathogens. Furthermore, hospital-based GNI specialists offer insight into how they treat GNIs in response to growing drug resistance.
QUESTIONS ANSWERED
- What are the most prescribed first-, second-, and third-line therapies for inpatients with urinary tract infections, nosocomial pneumonia, or complicated intra-abdominal infections?
- How are physicians approaching the treatment of infections caused by drug-resistant pathogens?
- Which clinical and nonclinical factors drive, and limit, the prescribing of branded agents such as Avycaz, Zerbaxa, Zemdri, Xerava, and Nuzyra?
- What will be the impact of recently approved agents such as Xacduro? What will drive use of such therapies, and in which infection types will they be used? Which current agents will be most affected?
PRODUCT DESCRIPTION Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.
CONTENT HIGHLIGHTS
Geography: United States
Primary research: Survey of 100 U.S. hospital-based infectious disease and critical care specialists
Key drugs covered: Avycaz, Fetroja, Nuzyra, Recarbrio, Xacduro, Xerava, Zemdri, Zerbaxa
Nuno Antunes, D.V.M., Ph.D., is a director on the Infectious, Niche, and Rare Diseases team at Decision Resources Group. Prior to this role, he was a senior analyst on the Global Market Access Insights team, where he served as a lead expert in market access, pricing and reimbursement, health technology assessment, and health policy in Latin American countries. He has extensive experience in the study of mechanisms of antibiotic resistance and in the development of novel antibiotics. He obtained his Ph.D. from the Universidad de Las Palmas de Gran Canaria in Spain.